eleven
heterocycl
schiff
base
aminohydroxyguanidin
tosyl
sbahg
compound
xi
test
antivir
activ
herp
simplex
viru
type
adenoviru
type
ad
via
plaqu
reduct
viru
yield
reduct
assay
work
undertaken
test
hypothesi
low
molecular
weight
sbahg
free
sb
make
better
antivir
agent
high
mw
sbahg
mw
plaqu
reduct
assay
method
demonstr
three
compound
vii
ix
moder
activ
inhibitori
concentr
ic
valu
mm
respect
ad
compound
viii
xi
exhibit
moder
activ
ic
valu
mm
respect
among
compound
screen
compound
pyridyl
methylen
tosyl
promis
antivir
candid
select
indic
si
ad
respect
viru
yield
reduct
assay
indic
compound
less
antivir
potenc
ad
antivir
effect
compound
high
input
viru
multipl
infect
moi
indic
compound
effect
antiadenovir
activ
h
post
infect
work
demonstr
sbahg
moder
antivir
activ
ad
virus
gener
low
mw
sbahg
low
cytotox
host
cell
variou
schiff
base
aminohydroxyguanidin
tosyl
sbahg
develop
laboratori
potenti
antitumor
andor
antivir
agent
tai
et
al
tang
et
al
wang
et
al
koneru
et
al
hui
et
al
substitut
sbahg
contain
essenti
pharmacophor
hydroxyguanidin
hg
structur
similar
hydroxyurea
hu
thiosemicarbazon
tsc
ncarbamoyloxyurea
shown
fig
numer
potent
effect
antivir
agent
limit
use
cytotox
effect
host
develop
resist
virus
thu
current
research
drug
discoveri
focus
develop
novel
potent
chemotherapeut
agent
target
select
low
cytotox
well
combin
chemotherapi
enhanc
antivir
activ
overcom
problem
drug
resist
adenovirus
ad
ubiquit
dna
virus
endem
human
popul
around
world
sometim
caus
epidem
outbreak
respiratori
ocular
infect
fortyseven
differ
serotyp
ad
character
one
third
associ
varieti
human
diseas
horwitz
although
effect
oral
entericco
vaccin
prevent
diseas
ad
serotyp
vaccin
use
militari
licens
administr
civilian
common
adenoviru
serotyp
infect
children
attenu
spite
promis
result
achiev
nucleosid
analogu
hpmpa
norcycl
gmp
cidofovir
see
fig
ganciclovir
adenovir
infect
vitro
gordon
et
al
vivo
anim
model
none
yet
avail
clinic
use
interferon
may
also
benefici
effect
mistchenko
falcoff
largescal
synthesi
prohibit
expens
thu
seriou
need
exist
develop
specif
agent
treat
adenovirusinduc
diseas
human
previous
mention
sbahg
synthes
earlier
laboratori
exhibit
antivir
activ
rou
sarcoma
viru
coronaviru
ad
tai
et
al
wang
et
al
hui
et
al
respect
compound
ic
micromolar
rang
ad
ad
found
hui
et
al
henc
postul
synthesi
new
sbahg
proper
structur
featur
could
yield
potent
use
antivir
agent
two
indepen
dent
studi
publish
earlier
indic
heterocycl
system
particularli
pyridin
isoquinolin
deriv
superior
biolog
activ
aromat
heteroaromat
system
blanz
et
al
spector
et
al
also
note
sbahg
synthes
use
benzaldehyd
salicylaldehyd
picolinaldehyd
isoquinolinaldehyd
singl
ring
aromat
heterocycl
compound
appar
better
antivir
activ
bulkier
sbahg
thu
confirm
hypothesi
two
new
heterocycl
sbahg
contain
picolinaldehyd
ring
system
synthes
screen
along
nine
heterocycl
sbahg
antiadenovir
antiherpesvir
activ
eleven
heterocycl
sbahg
screen
antivir
activ
ad
mcewen
strain
provid
yj
gordon
eye
ear
institut
pittsburgh
pittsburgh
pa
mckrae
strain
laboratori
strain
chemic
structur
compound
shown
fig
compound
pyridyl
methylen
amino
tosyl
ii
pyridyl
methylen
amino
tosyl
newli
synthes
compound
previous
synthes
laboratori
compound
iii
tai
et
al
compound
iv
v
wang
et
al
compound
vi
viii
tang
et
al
compound
ix
xi
koneru
et
al
synthesi
chemic
properti
new
compound
report
elsewher
da
et
al
cidofovir
gilead
scienc
foster
citi
ca
use
posit
control
ad
acyclovir
glaxo
wellcom
research
triangl
park
nc
use
posit
control
stock
solut
compound
except
cidofovir
prepar
solut
dmso
stock
compound
cidofovir
prepar
fresh
doubledistil
water
filtersteril
final
concentr
dmso
test
solut
exceed
human
lung
tumor
cell
american
type
cultur
collect
atcc
certifi
cell
line
ccl
c
use
host
cell
plaqu
assay
ad
mcewen
strain
vero
cell
atcc
ccl
c
african
green
monkey
kidney
cell
use
host
cell
plaqu
assay
mckrae
strain
cell
grown
monolay
minimum
essenti
medium
mem
previous
describ
da
et
al
cell
maintain
c
carbon
dioxid
atmospher
ad
mcewen
strain
mckrae
strain
grown
titer
respect
cell
line
mention
viru
stock
store
aliquot
c
determin
cytotox
concentr
compound
screen
confluent
monolay
vero
cell
expos
variou
concentr
antivir
agent
ixi
ahg
ts
posit
control
similar
procedur
use
hui
et
al
stock
solut
compound
serial
dilut
growth
medium
obtain
final
concentr
test
cytotox
triplic
well
tissu
cultur
plate
cosolv
dmso
control
run
dilut
test
compar
cell
control
rule
toxic
presenc
dmso
cytotox
base
abnorm
morpholog
chang
observ
cell
monolay
eg
clump
detach
round
cell
result
cytotox
observ
initi
screen
shown
tabl
plaqu
reduct
assay
determin
inhibitori
concentr
ic
vero
cell
grown
tissu
cultur
plate
upon
confluenc
cell
infect
plaqueform
unit
pfu
viru
per
well
similar
procedur
use
hui
et
al
experi
cell
product
infecti
viru
particl
viru
yield
time
cours
basi
infect
ad
conduct
compound
promis
antivir
candid
cell
grown
monolay
tissu
cultur
plate
upon
confluenc
freez
cell
supernat
sampl
harvest
h
postinfect
freezethaw
twice
centrifug
rpm
min
remov
cellular
debri
supernat
serial
dilut
titrat
cell
monolay
ascertain
viru
titer
viru
yield
similar
procedur
adopt
use
vero
cell
monolay
plate
inocul
approxim
pfu
per
well
treat
mm
compound
viru
yield
plot
hour
postinfect
use
microsoft
excel
ver
microsoft
excel
result
shown
fig
determin
toxic
concentr
tc
effect
compound
cell
growth
also
evalu
quantit
determin
tc
valu
vero
cell
procedur
modif
method
describ
de
clercq
et
al
tc
valu
compound
viiix
xi
determin
use
growth
medium
select
compound
serial
dilut
stock
obtain
concentr
rang
mm
maximum
mm
case
adl
base
result
preliminari
cytotox
studi
vero
cell
grown
tissu
cultur
plate
approxim
confluenc
triplic
well
expos
variou
concentr
drug
growth
medium
three
cell
control
well
receiv
growth
medium
drug
day
incub
monolay
nearli
confluent
medium
remov
monolay
trypsin
cell
count
use
coulter
counter
data
convert
determin
live
cell
dose
respons
curv
plot
determin
tc
use
program
use
determin
ic
valu
select
index
measur
margin
safeti
antivir
agent
determin
ratio
tc
ic
result
shown
tabl
medium
remov
monolay
inocul
approxim
pfu
viru
per
well
incub
h
frequent
rock
viral
inoculum
remov
monolay
wash
three
time
hank
balanc
salt
solut
six
well
receiv
ml
growth
medium
contain
mm
compound
anoth
six
well
receiv
growth
medium
drug
cell
cultur
incub
co
humidifi
atmospher
period
interv
h
infect
duplic
sampl
group
collect
separ
scrape
cell
plate
vero
cell
reveal
compound
vi
nontox
confluent
cell
mm
maximum
concentr
test
case
compound
viixi
cytotox
tabl
observ
abnorm
morpholog
chang
cell
monolay
eg
clump
detach
round
cell
thu
plaqu
reduct
assay
compound
vii
xi
conduct
concentr
mm
compound
viii
xi
inhibit
ad
concentr
b
mm
compound
viii
xi
also
cytotox
host
cell
concentr
mm
ic
valu
ad
mm
compound
mm
compound
viii
mm
compound
xi
respect
compound
vii
ix
found
moder
activ
ic
valu
mm
respect
therefor
conclud
heterocycl
sbahg
moder
antiadenovir
antiherpesvir
activ
compound
demonstr
activ
virus
dose
respons
plot
shown
fig
inhibit
virus
compound
follow
concentrationdepend
manner
reduct
virus
achiev
mm
respect
ic
tc
si
valu
five
compound
interest
summar
tabl
yield
reduct
assay
carri
compound
promis
antivir
candid
ad
ic
mm
vs
ic
mm
cidofovir
posit
control
ic
mm
vs
ic
mm
acyclovir
posit
control
higher
concentr
approxim
three
time
ic
compound
use
compound
nontox
vero
cell
concentr
mm
higher
multipl
infect
virus
use
assay
approxim
pfu
viru
use
infect
cell
monolay
instead
pfu
typic
use
plaqu
reduct
assay
advantag
assay
use
studi
effect
antivir
agent
viru
growth
cycl
highinput
multipl
challeng
viru
yield
reduct
assay
ad
fig
indic
compound
inhibit
adenoviru
multipl
earli
stage
infect
within
h
maintain
lower
yield
viru
particl
compar
viru
control
durat
least
day
h
yield
infecti
viru
maxim
reduc
log
h
post
infect
appar
increas
number
viru
particl
treat
cell
almost
rate
control
cell
result
resembl
earlier
studi
ad
structur
similar
compound
hui
et
al
support
observ
sbahg
probabl
inhibit
earli
stage
viru
replic
howev
viru
yield
reduct
assay
fig
b
appar
reduct
yield
compound
h
post
infect
modest
reduct
sevenfold
h
reduct
one
log
unit
h
indic
sbahg
differ
pharmacokinet
profil
ad
among
heterocycl
sbahg
test
antivir
activ
compound
promis
antivir
agent
activ
ad
compound
also
least
cytotox
toward
host
cell
tc
mm
vero
cell
tc
mm
compar
compound
moder
antivir
activ
name
vii
ix
viii
xi
ad
compound
may
thu
potenti
develop
broadspectrum
antivir
agent
initi
screen
compound
divid
two
group
respect
morpholog
chang
cell
name
group
noncytotox
compound
ivi
group
ii
cytotox
compound
viiixi
five
sbahg
mw
b
compound
iiii
v
vi
group
found
noncytotox
mm
concentr
cell
line
one
compound
iv
six
sbahg
group
still
noncytotox
mm
concentr
contrast
five
group
ii
sbahg
mw
compound
vii
xi
cytotox
mm
tabl
present
work
support
hypothesi
smaller
compound
mw
approxim
free
sb
gener
less
cytotox
potenti
better
antivir
agent
bulkier
compound
wang
et
al
compound
vii
xi
mw
free
schiff
base
highli
cytotox
host
cell
thu
may
potenti
effect
antitumor
agent
sinc
cytotox
transform
cell
import
featur
antitumor
activ
fact
earlier
studi
sbahg
compound
viixi
demonstr
potent
antineoplast
activ
compound
koneru
et
al
compound
vii
viii
ic
valu
mm
respect
cultur
murin
leukemia
cell
line
tang
et
al
compound
ix
xi
potent
cytotox
human
lymphoblast
leukemia
cell
line
ic
valu
mm
respect
koneru
et
al
antitumor
activ
hydroxyurea
hydroxyguanidin
thiosemicarbazon
schiff
base
aminohydroxyguanidin
due
abil
inhibit
enzym
ribonucleotid
reductas
rr
key
enzym
requir
de
novo
dna
synthesi
cell
cori
et
al
howev
antivir
activ
substitut
sbahg
may
may
due
rr
inhibit
alon
sinc
compound
effect
dna
virus
adenoviru
hui
et
al
rna
virus
coronaviru
murin
hepat
viru
mhv
wang
et
al
rna
tumor
virus
rou
sarcoma
viru
rsv
tai
et
al
earlier
studi
show
antitumor
activ
sbahg
correl
significantli
rr
inhibit
correl
exist
rr
inhibit
antivir
activ
quantit
structureact
relationship
qsar
analysi
sbahg
growth
cell
transform
chick
embryo
fibroblast
rsv
vitro
lien
et
al
howev
inhibit
rr
mechan
antivir
activ
rule
sinc
mechanist
studi
inhibit
virusinduc
rr
sbahg
conduct
wang
et
al
propos
antitumor
antivir
activ
sbahg
due
potenti
chelat
dival
metal
ion
import
cofactor
variou
enzymat
activ
also
postul
probabl
mechan
antiadenovir
activ
sbahg
chelat
zinc
ion
zn
serv
part
zinc
finger
motif
present
one
two
major
protein
encod
immedi
earli
region
gene
product
adenoviru
hui
et
al
express
gene
product
essenti
transcript
earli
viral
mrna
arena
antivir
chemotherapi
desir
achiev
select
toxic
toward
viru
minimum
toxic
effect
host
cell
mention
earlier
rapid
develop
resist
strain
viru
pose
seriou
threat
treatment
avail
antivir
agent
research
field
still
warrant
develop
effect
antivir
agent
